TY - JOUR T1 - Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 313 LP - 318 DO - 10.2967/jnumed.120.243840 VL - 62 IS - 3 AU - Yubin Miao AU - Thomas P. Quinn Y1 - 2021/03/01 UR - http://jnm.snmjournals.org/content/62/3/313.abstract N2 - Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin α4β1) are 2 attractive molecular targets for developing peptide radiopharmaceuticals for melanoma imaging and therapy. MC1R- and VLA-4–targeting peptides and peptide-conjugated Cornell prime dots (C′ dots) can serve as delivery vehicles to target both diagnostic and therapeutic radionuclides to melanoma cells for imaging and therapy. This review highlights the advances of MC1R- and VLA-4–targeted radiolabeled peptides and peptide-conjugated C′ dots for melanoma imaging and therapy. The promising preclinical and clinical results of these new peptide radiopharmaceuticals present an optimistic outlook for clinical translation into receptor-targeting melanoma imaging and radionuclide therapy in the future. ER -